Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Callit, bang on mate, thatโs exactly how I read it when I saw the rns this morning. Volz know the game really well.
Volz already supply the German and Slovak health services, so they will have good visibility into the kinds of masks their customers would like. I think they have progressed the 5-ply because they know there are customers who are wanting that extra protection in more risky activities.
Hurry up ShareHunter get your 10% mate your ramping is off the scale...
Boom - ready to pop...!
Update on new product development
The Company is pleased to announce that the 5-ply version of its Pro-Larva anti-viral mask, developed with Volz Filters UK Ltd ("Volz"), has been approved by the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"). The 5-ply mask has an additional filter layer, produced by Volz, after the hydrophobic outer layer, further strengthening the mask's already excellent bacterial filter efficiency.
The last year has established a close working relationship between Volz and the Company's subsidiary, Pharm 2 Farm Ltd ("P2F"). Not only is Volz manufacturing the existing 4-ply anti-viral masks for P2F, but the two companies have also been working on developing a new anti-viral filter material, as an extension of the work on the anti-viral mask and covered by the same patent. This new material has passed the proof-of-concept stage and Volz and P2F are now looking at how this could be commercialised (for example, in heating, ventilation and air conditioning systems), although this is expected to take several months, with work required on moving from proof-of-concept to large scale production.
Antony Legge, Executive Chairman, said; "Volz have been an excellent partner to Pharm 2 Farm, providing support in a number of areas. We are delighted with the MHRA approval for the 5-ply mask and to be working with Volz on an exciting development of the a-virion technology, with the potential to incorporate it into air filters."
Update on new product development
The Company is pleased to announce that the 5-ply version of its Pro-Larva anti-viral mask, developed with Volz Filters UK Ltd ("Volz"), has been approved by the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"). The 5-ply mask has an additional filter layer, produced by Volz, after the hydrophobic outer layer, further strengthening the mask's already excellent bacterial filter efficiency.
The last year has established a close working relationship between Volz and the Company's subsidiary, Pharm 2 Farm Ltd ("P2F"). Not only is Volz manufacturing the existing 4-ply anti-viral masks for P2F, but the two companies have also been working on developing a new anti-viral filter material, as an extension of the work on the anti-viral mask and covered by the same patent. This new material has passed the proof-of-concept stage and Volz and P2F are now looking at how this could be commercialised (for example, in heating, ventilation and air conditioning systems), although this is expected to take several months, with work required on moving from proof-of-concept to large scale production.
Antony Legge, Executive Chairman, said; "Volz have been an excellent partner to Pharm 2 Farm, providing support in a number of areas. We are delighted with the MHRA approval for the 5-ply mask and to be working with Volz on an exciting development of the a-virion technology, with the potential to incorporate it into air filters."